Macrogenics provides corporate update and 2022 financial results

Rockville, md., march 15, 2023 (globe newswire) -- macrogenics, inc. (nasdaq: mgnx), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the year ended december 31, 2022.
MGNX Ratings Summary
MGNX Quant Ranking